Oxford Nanopore Technologies (ONT) H2 2025 TU earnings summary

Executive summary

• Full year 2025 revenue expected at £223–£224 million, up 22% reported and 24% at constant currency compared to FY24, slightly exceeding guidance.

• Broad-based growth achieved across all geographies, customer end markets, and product categories.

• Continued progress on the path to profitability, with strong commercial momentum.

Financial highlights

• Revenue for FY25 projected at £223–£224 million, up from £183.2 million in FY24.

• Clinical revenue grew approximately 60% year-over-year; BioPharma up 30%; Applied Industrial up 27%; Research up 15%.

• PromethION product range led growth, increasing over 40% year-over-year.

Outlook and guidance

• Revenue growth for FY25 slightly ahead of the 20–23% constant currency guidance range.

• Management to announce preliminary annual results on 2 March 2026.